The Interrelationship between Insulin-Like Growth Factor 1, Apolipoprotein E ε4, Lifestyle Factors, and the Aging Body and Brain

  title={The Interrelationship between Insulin-Like Growth Factor 1, Apolipoprotein E $\epsilon$4, Lifestyle Factors, and the Aging Body and Brain},
  author={Sara A. Galle and Ilse K. Geraedts and Jan Berend Deijen and M. V. Milders and Madeleine L. Drent},
  journal={The Journal of Prevention of Alzheimer's Disease},
Aging is associated with a decrease in body and brain function and with a decline in insulin-like growth factor 1 levels. The observed associations between alterations in insulin-like growth factor 1 levels and cognitive functioning and Mild Cognitive Impairment suggest that altered insulin-like growth factor 1 signaling may accompany Alzheimer’s disease or is involved in the pathogenesis of the disease. Recent animal research has suggested a possible association between insulin-like growth… 

Diverse Roles of Ceramide in the Progression and Pathogenesis of Alzheimer’s Disease

The ceramide synthesis pathway and its involvement in the dysregulation of homeostasis, which eventually leads to AD is described and different therapeutics proposed to modulate the ceramide pathway to maintain ceramide levels and prevent the disease progression are referenced.



Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

The present work demonstrates extensive abnormalities in insulin and insulin-like growth factor type I and II (IGF-I and IGF-II) signaling mechanisms in brains with AD, and shows that while each of the corresponding growth factors is normally made in central nervous system neurons, the expression levels are markedly reduced in AD.

Insulin-like growth factor I (IGF-I) and cognitive decline in older persons

Growth hormone, insulin-like growth factor-1 and the aging brain

Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease

The data strongly support the notion that the authors must shift toward the implementation of multimodal rather than unimodal diagnostic and therapeutic strategies for AD, and suggest that brain insulin resistance and deficiency must also be therapeutically targeted to halt AD progression or reverse its natural course.

Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer’s Disease

While eight out of the nine studies included in this meta-analysis detected a statistically significant increase or decrease in serum levels of IGF-1 in Alzheimer’s disease subjects, the analysis as a whole did not show a significant trend in either direction, suggesting IGF- 1 level is likely a critical personalized factor.

Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy

Lower serum levels of IGF-1 are associated with an increased risk of developing AD dementia and higher levels with greater brain volumes even among middle-aged community-dwelling participants free of stroke and dementia.

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

The A β-dependent and Aβ-independent mechanisms that link Apo-E4 status with AD risk are discussed, and how to design effective strategies for AD therapy by targeting ApO-E is considered.